Asset
Soquelitinib
Corvus Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03952078 | phase1 | active_not_recruiting | 2019-05-03 | 2026-04-30 | Corvus Pharmaceuticals, Inc. | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma |
FDA applications (0)
This company has no applications containing this asset.